← Eichor
Study identifier: NCT07313475 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of the Cryocheck HexLA Integrated TCA for the Detection of Lupus Anticoagulant

Condition: Lupus Anticoagulant  ·  Sponsor: University Hospital, Strasbourg, France

PhaseN/A
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Lupus anticoagulant (LA) testing is performed using two screening tests: activated partial thromboplastin time (APTT) and diluted Russell's viper venom time. If one of the screening tests is positive, a confirmation test based on the same principle is performed. The HUS Hematology Laboratory uses an integrated APTT for LA testing, consisting of a screening reagent: Cephen LS, and a confirmation reagent: Cephen (Hyphen Biomed). The aim of this study is to determine whether another integrated activated partial thromboplastin time (APTT) test, Cryocheck HexLA, offers better performance than Cephen LS/Cephen, both in terms of sensitivity to lupus anticoagulant (LA) and susceptibility to interference from anticoagulant treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Agathe HERB, PharmD  ·  33 3 88 12 75 53  ·  agathe.herb@chru-strasbourg.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Laboratoire d'Hématologie - CHU de Strasbourg - FranceStrasbourg, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07313475